IQVIA™ Real-World Insights Bibliography

Dutch health state utilities for infertility and subfertility.
Author(s): Krol M, Nap A, Michels RM, Veraart CPWM, Goossens LMA
Affiliations(s): IQVIA, Netherlands
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Abstract,
Countries: Netherlands,
C:
Y:
Health economics, Health status & patient reported outcomes,
2018
  L:
A:
English
Quality of life, Utility analysis,
  Add to report
 
 
Cost effectiveness of cladribine tablets for treatmetn of RMS in The Netherlands.
Author(s): De Francesco M1, Mahajan K2, Michels R3, Schiffers K4, Budhia S5, Harty G5, Krol M3
Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, India Michels 3 IQVIA, Netherlands 4 Merck, Netherlands 5 Merck, UK
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Abstract,
Countries: Netherlands,
C:
Y:
Neurological disorders,
2018
  L:
A:
English
Cost effectiveness, Cost utility,
  Add to report
 
 
Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study.
Author(s): Buijs S1, Krol M2, de Voer G3
Affiliations(s): 1 Healthcare Insights, Netherlands 2 IQVIA, Netherlands 3 Merck, Netherlands
Publication(s):  Journal of Comparative Effectiveness Research, 2018, Vol. 7, No. 5
Document Type(s): Article,
Countries: Netherlands,
Click here for the abstract
C:
Y:
Neurological disorders,
2018
  L:
A:
English
Cost of illness,
  Add to report
 
 
TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES
Author(s): Norrbacka K, Divino V, Boye K, Lebrec J, Dekoven M
Affiliations(s): Eli Lilly, IQVIA
Publication(s):  ISPOR Europe 2018
Document Type(s): Poster,
Countries: Belgium, Canada, France, Germany, Italy, Netherlands,
Click here for the abstract
C:
Y:
Diabetes,
2018
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis
Author(s): Marieke Krol1, Gert de Voer2, Ulrike Osowski3
Affiliations(s): 1QuintilesIMS, Capelle aan den Ijssel, the Netherlands; 2Merck B.V., Schiphol-Rijk, the Netherlands; 3Merck KGaA, Darmstadt, Germany
Publication(s):  Patient Preference and Adherence 2017:11 1189–1196
Document Type(s): Article,
Countries: Germany, Netherlands,
C:
Y:
Gastrointestinal disorders,
2017
  L:
A:
English
Retrospective cohort analysis, Retrospective database analysis,
  Add to report
 
 
Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model
Author(s): Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7
Affiliations(s): 1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany
Publication(s):  JHEOR 2017;5(1):89-108
Document Type(s): Article,
Countries: Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK,
C:
Y:
Immunology and Vaccination, Infectious disease, Respiratory disease,
2017
  L:
A:
English
Epidemiological study, Public Health,
  Add to report
 
 
Patient adherence to subcutaneous IFN beta-1a injections using the Rebismart® injection device:a retrospective real-world among Dutch and German patients with multiple sclerosis.
Author(s): Krol M1, deVoer G2, Osowski U3
Affiliations(s): 1 QuintilesIMS, The Netherlands 2 Merck B.V., Schiphol-Rijk, the Netherlands 3 Merck KGaA, Darmstadt, Germany
Publication(s): 
Document Type(s): Article,
Countries: Germany, Netherlands,
Click here for the abstract
C:
Y:
Neurological disorders,
2017
  L:
A:
English
clinical setting: Secondary care, Compliance, Retrospective database analysis,
  Add to report
 
 
Evaluation of the effectiveness of risk minimisation measures: a survey among health care professionals to assess their knowledge and attitudes on prescribing conditions of Instanyl® in France and the Netherlands.
Author(s): Toussi M1, Garofano A1, Jouaville L1, Bardoulat I1, Mitrofan L1
Affiliations(s): 1 QuintilesIMS, La Défense, France
Publication(s):  33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2017, August 26-30, Montreal, Canada
Document Type(s): Poster,
Countries: France, Netherlands,
C:
Y:
Drug safety, Pain, Risk Management & REMS,
2017
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Public Health, Survey research,
  Add to report
 
 
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Author(s): Divino V., DeKoven M., Khan FA., Boye KS., Sapin H., Norrbacka K.
Affiliations(s): Lilly. IMS authors: Divino V, DeKoven M
Publication(s):  Diabetes Ther.
Document Type(s): Article,
Countries: Belgium, France, Germany, Netherlands, Sweden,
Click here for the abstract
C:
Y:
Diabetes,
2017
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
SCHÉMAS THÉRAPEUTIQUES ET POSOLOGIQUES CHEZ DES PATIENTS AVEC UN DIABÈTE DE TYPE 2 (DT2) INITIANT UN TRAITEMENT PAR AGONISTE DU RÉCEPTEUR DU GLUCAGON-LIKE PEPTIDE 1 (AR GLP-1) EN EUROPE
Author(s): Norrbacka K, Divino V, Dekoven M, Boye KS
Affiliations(s): Eli Lilly, IQVIA
Publication(s):  Societé Francophone du Diabete 2017
Document Type(s): Poster,
Countries: Belgium, Canada, France, Germany, Italy, Netherlands,
Click here for the abstract
C:
Y:
Diabetes,
2017
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
 1 of 5 Next Page Last Page